Clinical trials sponsored by Betta Pharmaceuticals Co., Ltd.
3
Recruiting trials
8
Conditions studied
Phase breakdown
Phase 1 1Phase 2 2Phase 3 1
Conditions studied
| Condition | Trials |
|---|---|
| Lung cancer | 3 |
| Non-Small Cell Lung Cancer | 2 |
| Adjuvant Drug Therapy | 1 |
| Colorectal Cancer | 1 |
| EGFR | 1 |
| Head and Neck Cancer | 1 |
| NSCLC | 1 |
| Solid Tumor | 1 |
Recruiting trials led by Betta Pharmaceuticals Co., Ltd.
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer
- Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Common questions
How many trials is Betta Pharmaceuticals Co., Ltd. recruiting for?
Betta Pharmaceuticals Co., Ltd. is the lead sponsor of 3 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.